Incyte's Jakafi Fails Phase-III Trial

Incyte Corporation (INCY) announced yesterday that its experimental drug Jakafi (ruxolitinib) failed in phase-III trials as it did not achieve its primary endpoint of controlling and improving symptom conditions in patients diagnosed with polycythemia vera (PV). The RELIEF trial tested the effectiveness of ruxolitinib on a sample population, and compared results to hydroxyurea (HU). However, the former did not generate statistically significant findings that could get a marketing approval for th...